Literature DB >> 19002442

Cytochrome P450 2C19 genetic polymorphisms in Ugandans.

Jun Miura, Celestino Obua, Catherine Abbo, Sunao Kaneko, Tomonori Tateishi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19002442     DOI： 10.1007/s00228-008-0583-6

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  12 in total

1.  Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population.

Authors:  L Bathum; E Skjelbo; T K Mutabingwa; H Madsen; M Hørder; K Brøsen
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

2.  Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden.

Authors:  Eleni Aklillu; Karin Herrlin; Lars L Gustafsson; Leif Bertilsson; Magnus Ingelman-Sundberg
Journal:  Pharmacogenetics       Date:  2002-07

3.  Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers.

Authors:  R Michael Baldwin; Staffan Ohlsson; Rasmus Steen Pedersen; Jessica Mwinyi; Magnus Ingelman-Sundberg; Erik Eliasson; Leif Bertilsson
Journal:  Br J Clin Pharmacol       Date:  2008-02-20       Impact factor: 4.335

4.  Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population.

Authors:  Katsuyoshi Sugimoto; Tsukasa Uno; Hiroshi Yamazaki; Tomonori Tateishi
Journal:  Br J Clin Pharmacol       Date:  2008-01-30       Impact factor: 4.335

5.  A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants.

Authors:  Sarah C Sim; Carl Risinger; Marja-Liisa Dahl; Eleni Aklillu; Magnus Christensen; Leif Bertilsson; Magnus Ingelman-Sundberg
Journal:  Clin Pharmacol Ther       Date:  2006-01       Impact factor: 6.875

6.  Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients.

Authors:  Mateusz Kurzawski; Barbara Gawrońska-Szklarz; Joanna Wrześniewska; Andrzej Siuda; Teresa Starzyńska; Marek Droździk
Journal:  Eur J Clin Pharmacol       Date:  2006-08-16       Impact factor: 2.953

7.  Genetic polymorphism of CYP2D6 and CYP2C19 in east- and southern African populations including psychiatric patients.

Authors:  C Dandara; C M Masimirembwa; A Magimba; J Sayi; S Kaaya; D K Sommers; J R Snyman; J A Hasler
Journal:  Eur J Clin Pharmacol       Date:  2001-04       Impact factor: 2.953

8.  Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19.

Authors:  J H Wang; Z Q Liu; W Wang; X P Chen; Y Shu; N He; H H Zhou
Journal:  Clin Pharmacol Ther       Date:  2001-07       Impact factor: 6.875

9.  Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype.

Authors:  K Herrlin; A Y Massele; M Jande; C Alm; G Tybring; Y A Abdi; A Wennerholm; I Johansson; M L Dahl; L Bertilsson; L L Gustafsson
Journal:  Clin Pharmacol Ther       Date:  1998-10       Impact factor: 6.875

10.  Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients.

Authors:  I Rudberg; B Mohebi; M Hermann; H Refsum; E Molden
Journal:  Clin Pharmacol Ther       Date:  2007-07-11       Impact factor: 6.875
View more
  6 in total

1.  Evaluation of lansoprazole as a probe for assessing cytochrome P450 2C19 activity and genotype-phenotype correlation in childhood.

Authors:  Ersin Gumus; Ozgur Karaca; Melih O Babaoglu; Gökhan Baysoy; Necati Balamtekin; Hulya Demir; Nuray Uslu; Atilla Bozkurt; Aysel Yuce; Umit Yasar
Journal:  Eur J Clin Pharmacol       Date:  2011-11-11       Impact factor: 2.953

Review 2.  Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17.

Authors:  Alain Li-Wan-Po; Thierry Girard; Peter Farndon; Candy Cooley; James Lithgow
Journal:  Br J Clin Pharmacol       Date:  2010-03       Impact factor: 4.335

Review 3.  Interethnic variation of CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes across world populations.

Authors:  I Fricke-Galindo; C Céspedes-Garro; F Rodrigues-Soares; M E G Naranjo; Á Delgado; F de Andrés; M López-López; E Peñas-Lledó; A LLerena
Journal:  Pharmacogenomics J       Date:  2015-10-27       Impact factor: 3.550

4.  Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations.

Authors:  Rasmus S Pedersen; Charlotte Brasch-Andersen; Sarah C Sim; Troels K Bergmann; Jónrit Halling; Maria S Petersen; Pál Weihe; Hege Edvardsen; Vessela N Kristensen; Kim Brøsen; Magnus Ingelman-Sundberg
Journal:  Eur J Clin Pharmacol       Date:  2010-07-28       Impact factor: 2.953

5.  CYP2C19 polymorphism frequency in Russian patients in Central Russia and Siberia with acute coronary syndrome.

Authors:  Karin B Mirzaev; Elena M Zelenskaya; Olga L Barbarash; Vladimir I Ganyukov; Konstantin A Apartsin; Natalya O Saraeva; Konstantin Y Nikolaev; Kristina A Ryzhikova; Galina I Lifshits; Dmitry A Sychev
Journal:  Pharmgenomics Pers Med       Date:  2017-04-12

6.  Inconsistency in race and ethnic classification in pharmacogenetics studies and its potential clinical implications.

Authors:  Frederick Zhang; Joseph Finkelstein
Journal:  Pharmgenomics Pers Med       Date:  2019-07-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.